Day: November 9, 2022

2′-fluoro-5-[11C]-methyl-1-β-d-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET was written by Conti, Peter S.; Alauddin, Mian M.; Fissekis, John R.; Schmall, Bernard; Watanabe, Kyochi A.. And the article was included in Nuclear Medicine and Biology on August 31,1995.SDS of cas: 69256-17-3 The following contents are mentioned in the article:

Rapid in vivo catabolism limits the use of currently available radiotracers used in tumor proliferation studies with positron emission tomog. (PET). This is manifested by the need to develop complex math. models to interpret kinetic and metabolite data obtained from imaging studies with agents such as carbon-11 labeled thymidine. A potential carbon-11 labeled radiotracer for cellular proliferation, 2′-fluoro-5-([11C]-methyl)-1-β-D-arabinofuranosyluracil (FMAU), has been prepared using a previously described method for preparation of [11C]methyl-thymidine where selective alkylation of a pyrimidyl dianion is accomplished with [11C]methyl iodide at the 5-position of the pyrimidine ring. FMAU shares many in vivo characteristics of thymidine, including cellular transport, phosphorylation by mammalian kinase, and incorporation into DNA. Most importantly, in vivo catabolism of FMAU is limited, potentially yielding simplified kinetic models for determination of cellular proliferation with positron emission tomog. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3SDS of cas: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine is an aromatic heterocyclic organic compound similar to pyridine. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.SDS of cas: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Synthesis and anti-HIV activity of several 2′-fluoro-containing pyrimidine nucleosides was written by Sterzycki, Roman Z.; Ghazzouli, Ismail; Brankovan, Vera; Martin, John C.; Mansuri, Muzammil M.. And the article was included in Journal of Medicinal Chemistry on August 31,1990.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Several 2′-fluoroarabino-2′,3′-dideoxy- and 2′-fluoro-2′,3′-unsaturated 2′,3′-dideoxy pyrimidine nucleoside analogs are reported. The saturated analogs 1-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)thymine or -uracil (I; R = Me or H, resp.) were readily prepared from the resp. 2′-deoxy-2′-fluoroarabinosyl nucleoside analog by radical deoxygenation of 3′-OH. The cytosine derivative II and the unsaturated compounds III and IV were also synthesized. The novel compounds were evaluated in vitro against human immunodeficiency virus (HIV) (LAV isolate). II was the most active of the newly synthesized substances against HIV with an ID50 of 0.8 μg/mL; ddC had an ID50 of 0.00m μg/mL. Because of its potency in the initial tests, II was further evaluated in both T cells and macrophage/monocyte cell lines, with several different isolates of HIV. Although II exhibited good antiviral activity in these systems, it was less active than AZT in these assays. At 1 μM the inhibition of CFU-GM by II was found to be 35-40%; this is slightly higher than seen with AZT. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogs for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus was written by Ashida, Noriyuki; Watanabe, Yoko; Miura, Shinji; Kano, Fumitaka; Sakata, Shinji; Yamaguchi, Toyohumi; Suzutani, Tatsuo; Machida, Haruhiko. And the article was included in Antiviral Research on August 31,1997.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

We investigated structure-activity relationships of 5-substituted uracil nucleoside analogs for their selective antiviral activity against varicella-zoster virus (VZV) and affinity for VZV thymidine kinase (TK). Anti-proliferative activity of the compounds was measured using human lymphoblastoid cells. Most 2′-deoxyribofuranosyluracil, arabinofuranosyluracil (araU) and 2′-deoxy-2′-fluoro-arabinofuranosyluracil derivatives showed selective anti-VZV activity as well as activity against herpes simplex virus types 1 and 2. 2′-Deoxyuridine derivatives showed higher affinity than the corresponding araU analogs. A correlation was seen between the 50% EDs for VZV and the Ki values for VZV TK, except for 5-ethyl-2′-deoxyuridine and 5-Et araU that showed relatively high affinity for VZV TK without showing any activity against VZV. 5-Halogenovinyluracil nucleosides showed the highest affinity and the most potent and selective anti-VZV activity. 2′-Deoxy-2′-fluoro-arabinofuranosyluracil derivatives exhibited high anti-VZV potency though they showed relatively low affinity for VZV TK. Some 3′-deoxythymidine analogs having anti-human immunodeficiency virus activity were inactive against herpesviruses. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine nitrogenous bases are derived from the organic compound pyrimidine through the addition of various functional groups. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O’-alkyl analogs was written by Kierdaszuk, Borys; Krawiec, Krzysztof; Kazimierczuk, Zygmunt; Jacobsson, Ulla; Johansson, Nils G.; Munch-Petersen, Birgitte; Eriksson, Staffan; Shugar, David. And the article was included in Nucleosides & Nucleotides on August 31,1999.Recommanded Product: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one The following contents are mentioned in the article:

Nucleoside analogs with modified sugar moieties have been examined for their substrate/inhibitor specificities towards highly purified deoxycytidine kinase (dCK) and thymidine kinases (tetrameric high-affinity form of TK1-cytoplasmic and TK2-mitochondrial) from human leukemic spleen. In particular, the analogs included the mono- and di-O’-Me derivatives of dC, dU and dA, syntheses of which are described. In general, purine nucleosides with modified sugar rings were feebler substrates than the corresponding cytosine analogs. Sugar-modified analogs of dU were also relatively poor substrates of TK1 and TK2, but were reasonably good inhibitors, with generally lower Ki values vs TK2 than TK1. An excellent discriminator between TK1 and TK2 was 3′-hexanoylamino-2′,3′-dideoxythymidine, with a Ki of ∼600 μM for TK1 and ∼0.1 μM for TK2. 3′-OMe-dC was a superior inhibitor of dCK to its 5′-O-Me congener, consistent with possible participation of the oxygen of the (3′)-OH or (3′)-OMe as proton acceptor in hydrogen bonding with the enzyme. Surprisingly α-dT was a good substrate of both TK1 and TK2, with Ki values of 120 and 30 μM for TK1 and TK2, resp.; and a 3′-branched α-L-deoxycytidine analog proved to be as good a substrate as its α-D-counterpart. Several 5′-substituted analogs of dC were good non-substrate inhibitors of dCK and, to a lesser extent, of TK2. Finally, some ribonucleosides are substrates of the foregoing enzymes; in particular C is a good substrate of dCK, and 2′-OMe-C is an even better substrate than dC. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Recommanded Product: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. For example, the neurotoxin tetrodotoxin is a pyrimidine derivative. It is found in a number of species including the Japanese puffer fish, the blue-ringed octopus, and the orange-bellied newt. Tetrodotoxin prevents the transmission of nerve signals and can result in paralysis and death.Recommanded Product: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Anti-herpesvirus activity profile of 4′-thioarabinofuranosyl purine and uracil nucleosides and activity of 1-β-D-2′-fluoro-4′-thioarabinofuranosyl guanine and 2,6-diaminopurine against clinical isolates of human cytomegalovirus was written by Machida, Haruhiko; Ashida, Noriyuki; Miura, Shinji; Endo, Mikari; Yamada, Kohei; Kitano, Kenji; Yoshimura, Yuichi; Sakata, Shinji; Ijichi, Osamu; Eizuru, Yoshito. And the article was included in Antiviral Research on August 31,1998.Synthetic Route of C10H13FN2O5 The following contents are mentioned in the article:

Newly synthesized 4′-thio- and 2′-fluoro-4′-thioarabinofuranosyl purine and pyrimidine nucleosides were compared with the corresponding 4′-oxo type arabinosyl nucleosides for anti-herpesvirus and anti-cell proliferative potencies. 4′-Thioarabinosyl- and 2′-fluoro-4′-thioarabinofuranosyl 5-substituted uracils had selective antiviral activities, but were not superior to 4′-oxo nucleosides, except for the activity of 5-ethyluracil-4′-thio nucleosides against herpes simplex virus. Furthermore, 4′-thio substituted derivatives of sorivudine (BV-araU) and related compounds, and 2′-fluoro-5-methylarabinosyluracil exhibited reduced activity against varicella-zoster virus compared with the parent compounds The 4′-thioarabinosyluracils, except for 5-methyluracil derivatives, were inactive against human cytomegalovirus (HCMV). 4′-Thioarabinofuranosyl guanine and diaminopurine had the most potent anti-HCMV and anti-proliferative activities, whereas arabinosyl guanine and diaminopurine had only marginal antiviral activity. 2′-Fluoro-4′-thioarabinofuranosyl derivatives of guanine (4′-thio-FaraG) and 2,6-diaminopurine (4′-thio-FaraDAP), however, had particularly high activity against all herpesviruses tested with anti-proliferative activity equipotent to that of arabinosyl guanine and diaminopurine. 4′-Thio- and 2′-fluoro-4′-thioarabinofuranosyladenines exhibited biol. activities similar to that of arabinosyladenine. Both 4′-thio-FaraG and 4′-thio-FaraDAP had a 6-fold lower ED50 than ganciclovir against clin. isolates of HCMV. A ganciclovir-resistant isolate, obtained from a patient who had received long-term ganciclovir-treatment, was susceptible to 4′-thio-FaraG and 4′-thio-FaraDAP. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Synthetic Route of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine nitrogenous bases are derived from the organic compound pyrimidine through the addition of various functional groups. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Synthetic Route of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2 was written by Tehrani, Omid S.; Douglas, Kirk A.; Lawhorn-Crews, Jawana M.; Shields, Anthony F.. And the article was included in European Journal of Nuclear Medicine and Molecular Imaging on August 31,2008.Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Fluoropyrimidines like 1-(2′-deoxy-2′-fluoro-β-d-arabinofuranosyl)-thymine (FMAU) and 3′-deoxy-3′-fluorothymidine (FLT) accumulate in tumors and are being used as positron emission tomog. tumor-imaging tracers. Proliferating tissues with high thymidine kinase 1 (TK1) activity retain FLT; however, the mechanism of selective accumulation of FMAU in tumors and certain other tissues requires further study. Retention of [3H]FLT and [3H]FMAU was measured in prostate cancer cell lines PC3, LNCaP, DU145, and the breast cancer cell line MD-MBA-231, and the tracer metabolites were analyzed by high-performance liquid chromatog. (HPLC). FMAU retention, thymidine kinase 2 (TK2) activity, and mitochondrial mass were determined in cells stressed by depleted cell culture medium or by treating with oxidative, reductive, and energy stress, or specific adenosine monophosphate-activated protein kinase activator, or eIF2 inhibitor. TK1 and TK2 activities and mitochondrial mass were determined by FLT phosphorylation, 1-β-d-arabinofuranosylthymine (Ara-T) phosphorylation, and flow cytometry, resp. FMAU retention in rapidly proliferating cancer cell lines was five to ten times lower than FLT after 10 min incubation. HPLC anal. of the cellular extracts showed that phosphorylated tracers are the main retained metabolites. Nutritional stress decreased TK1 activity and FLT retention but increased retained FMAU. TK2 inhibition decreased FMAU retention and phosphorylation with negligible effects on FLT. Oxidative, reductive, or energy stress increased FMAU retention and correlated with mitochondrial mass (r2 = 0.88, p = 0.006). FMAU phosphorylation correlated with increased TK2 activity (r2 = 0.87, p = 0.0002). FMAU is preferably phosphorylated by TK2 and can track TK2 activity and mitochondrial mass in cellular stress. FMAU may provide an early marker of treatment effects. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.Name: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing was written by Fourel, Isabelle; Gripon, Philippe; Hantz, Oliver; Cova, Lucyna; Lambert, Veronique; Jacquet, Chantal; Watanabe, Kyoichi; Fox, Jack; Guillouzo, Christiane; Trepo, Christian. And the article was included in Hepatology (Philadelphia, PA, United States) on August 31,1989.HPLC of Formula: 69256-17-3 The following contents are mentioned in the article:

Duck cultured hepatocytes from Pekin ducks naturally infected by duck hepatitis B virus can remain functional twice longer if a coculture system with rat liver epithelial cells is used instead of ordinary primary culture. The use of a selective medium in which ornithine and lactate replaced arginine and glucose, resp., allowed viral replication initiated in vivo to be maintained in the coculture for 2 mo. Several antiviral compounds including the pyrophosphate analog (phosphonoformic acid) or nucleoside analogs (9β-arabinofuranosyl AMP, 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-iodocytosine, 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-ethyluracil and 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl thymine) were studied in both culture systems for their ability to inhibit duck hepatitis B virus replication. Hepatocytes were treated for 7 days with 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-ethyluracil (10 μM) and 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosylthymine (0.5 μM) or for 14 days with 9β-arabinofuranosyl AMP (90 μM), phosphonoformic acid (100 μM) and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (6 μM). The effects of the drugs on viral replication were monitored by testing for duck hepatitis B virus DNA in the culture supernatant and in the cells by mol. hybridization. All the above-mentioned drugs demonstrated an inhibitory activity in both types of cultures which at the quite distinct doses used was greater for phosphonoformic acid and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine than for 9β-arabinofuranosyl AMP, 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-ethyluracil or 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl thymine. Viral replication, however, resumed following discontinuation of treatment. More studies are needed to further confirm the relevance of this tissue culture system for the screening of new potential anti-hepatitis B virus agents. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3HPLC of Formula: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.HPLC of Formula: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine was written by Philips, Frederick S.; Feinberg, Aaron; Chou, Ting Chao; Vidal, Pedro M.; Su, Tsann Long; Watanabe, Kyoichi A.; Fox, Jack J.. And the article was included in Cancer Research on August 31,1983.HPLC of Formula: 56632-83-8 The following contents are mentioned in the article:

The pharmacologicl disposition and metabolic fate of 2-14C-labeled 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine (FMAU)(I) [69256-17-3] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine (FIAC)(II) [69123-90-6] were compared after giving each of the substances i.v. or orally. Most of the radioactivity of these substances is excreted in urine within 24 h after administration in mice and rats. During the same period, the recovery in feces and respiratory CO2 is, for each, < 5%. Biliary excretion from the common bile duct of rats is low, 2 to 4% of dose during the first 5 h after i.v. injection. Chromatog. anal. of 24-h urine collections after giving FMAU reveals that most of the radioactivity in mouse and rat urine is present as unchanged drug. Mouse urine also contains significant amounts of 3 unidentified metabolites of FMAU; these have also been detected in mouse plasma and in rat urine. Chromatog. analyses of plasma and urine samples from mice and rats given FIAC show that this substance is substantially transformed by deamination into a major metabolite, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-ioduracil  [69123-98-4]. Deiodinated metabolites have also been detected, namely, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine  [56632-83-8] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil  [69123-94-0]. Radioactivity in extracerebral organs of rats receiving labeled FIAC or FMAU is, within 10 min after i.v. injection, maximal and in concentrations equivalent to or higher than in plasma. Maximal concentrations after oral doses are reached within 30 to 60 min. At later times, rates of decrease in extracerebral organs parallel those in plasma. Half-lives after oral doses are higher than after i.v. doses. Penetration of radioactivity into rat brain is rapid, and the ratio of brain to plasma concentrations increases steadily to over 0.5 during the first 6 h after dosing. Substantially greater concentrations appear in brain after FMAU than after FIAC. Studies of radioactivity remaining in various portions of the gut of rats given oral doses of the labeled drugs suggest that most of the absorption takes place from the stomach or upper end of the small intestine. In dogs, the rates of renal clearance of FMAU and FIAC are less than 20% that of creatine when plasma concentrations are 10-fold greater than that inhibiting herpes virus replication in vitro by 90%. Nearly all of the radioactivity excreted in dog urine during the first 24 h after i.v. [2-14C]FMAU consists of unchanged drug. After [2-14C]FIAC, the 24-h urinary radioactivity is composed primarily of unchanged drug and the deiodinated metabolites, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil; only trace amounts of the deaminated product, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodouracil, were detected. The synthesis of [2-14C]FMAU [83374-60-1] is described. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8HPLC of Formula: 56632-83-8).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.HPLC of Formula: 56632-83-8

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine was written by Philips, Frederick S.; Feinberg, Aaron; Chou, Ting Chao; Vidal, Pedro M.; Su, Tsann Long; Watanabe, Kyoichi A.; Fox, Jack J.. And the article was included in Cancer Research on August 31,1983.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

The pharmacologicl disposition and metabolic fate of 2-14C-labeled 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine (FMAU)(I) [69256-17-3] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine (FIAC)(II) [69123-90-6] were compared after giving each of the substances i.v. or orally. Most of the radioactivity of these substances is excreted in urine within 24 h after administration in mice and rats. During the same period, the recovery in feces and respiratory CO2 is, for each, < 5%. Biliary excretion from the common bile duct of rats is low, 2 to 4% of dose during the first 5 h after i.v. injection. Chromatog. anal. of 24-h urine collections after giving FMAU reveals that most of the radioactivity in mouse and rat urine is present as unchanged drug. Mouse urine also contains significant amounts of 3 unidentified metabolites of FMAU; these have also been detected in mouse plasma and in rat urine. Chromatog. analyses of plasma and urine samples from mice and rats given FIAC show that this substance is substantially transformed by deamination into a major metabolite, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-ioduracil  [69123-98-4]. Deiodinated metabolites have also been detected, namely, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine  [56632-83-8] and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil  [69123-94-0]. Radioactivity in extracerebral organs of rats receiving labeled FIAC or FMAU is, within 10 min after i.v. injection, maximal and in concentrations equivalent to or higher than in plasma. Maximal concentrations after oral doses are reached within 30 to 60 min. At later times, rates of decrease in extracerebral organs parallel those in plasma. Half-lives after oral doses are higher than after i.v. doses. Penetration of radioactivity into rat brain is rapid, and the ratio of brain to plasma concentrations increases steadily to over 0.5 during the first 6 h after dosing. Substantially greater concentrations appear in brain after FMAU than after FIAC. Studies of radioactivity remaining in various portions of the gut of rats given oral doses of the labeled drugs suggest that most of the absorption takes place from the stomach or upper end of the small intestine. In dogs, the rates of renal clearance of FMAU and FIAC are less than 20% that of creatine when plasma concentrations are 10-fold greater than that inhibiting herpes virus replication in vitro by 90%. Nearly all of the radioactivity excreted in dog urine during the first 24 h after i.v. [2-14C]FMAU consists of unchanged drug. After [2-14C]FIAC, the 24-h urinary radioactivity is composed primarily of unchanged drug and the deiodinated metabolites, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)uracil; only trace amounts of the deaminated product, 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodouracil, were detected. The synthesis of [2-14C]FMAU [83374-60-1] is described. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Pyrimidine N-oxides. II. The synthesis of some amino- and iminopyrimidine N-oxides and related compounds was written by Cowden, William B.; Jacobsen, Noel W.. And the article was included in Australian Journal of Chemistry on September 30,1979.Computed Properties of C4H5ClN4O The following contents are mentioned in the article:

The course of peroxy acid oxidation of pyrimidinetriamines I (R = H, halogen, alkyl, NO2, etc.) and related compounds depends on the nature of R as well as on the nature of the amine groups in positions 4 and 6. Thus non-hydrolyzable R groups favor N-oxidation on the ring, whereas hydrolyzable R groups favor rearrangement to 6-amino-s-triazine-2,4-dione. This study involved multiple reactions and reactants, such as 2,6-Diamino-4-chloropyrimidine-1-oxide (cas: 35139-67-4Computed Properties of C4H5ClN4O).

2,6-Diamino-4-chloropyrimidine-1-oxide (cas: 35139-67-4) belongs to pyrimidine derivatives. Pyrimidine is an aromatic heterocyclic organic compound similar to pyridine. For example, the neurotoxin tetrodotoxin is a pyrimidine derivative. It is found in a number of species including the Japanese puffer fish, the blue-ringed octopus, and the orange-bellied newt. Tetrodotoxin prevents the transmission of nerve signals and can result in paralysis and death.Computed Properties of C4H5ClN4O

35139-67-4;2,6-Diamino-4-chloropyrimidine-1-oxide;The future of 35139-67-4;New trend of C4H5ClN4O;function of 35139-67-4